3034-3062

Regulatory Research and Medicine Evaluation

SCEEMP

Health Score

0 Excellent

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Deposit reference lists for 25 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact25 DOIs
2

Attach ORCID iDs across 22 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact22 DOIs
3

Add abstracts to 21 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact21 DOIs

DOIs for this ISSN

Showing the top 5 of 145 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Compounding Pharmacy Restoration as a Current Healthcare Pri… (10.30895/1991-2919-2024-14-4-380-385)
References ORCID
47.71 8
2 Antimicrobial Resistance Management Strategy: Current Challe… (10.30895/1991-2919-2025-15-1-8-12)
Abstract References ORCID
45.15 3
3 Role of Scientific Centre for Expert Evaluation of Medicinal… (10.30895/1991-2919-2025-15-5-492-496)
References ORCID
15.05 1
4 Approaches to Assessing the Quality of Fatty Oils and Medici… (10.30895/1991-2919-2024-14-6-634-644)
Abstract
7.53 1
5 Antimicrobial Resistance Development In Vitro: Adaptive Labo… (10.30895/1991-2919-2024-656)
Abstract
7.53 1
6 Current Approaches to Planning and Conducting Clinical Trial… (10.30895/1991-2919-2020-10-2-111-120)
0.00 1
7 Effect of Sample Preparation and Chromatographic Conditions… (10.30895/1991-2919-2020-10-2-121-128)
0.00 1
8 Determination of Anthracene Derivatives in the Antihaemorrho… (10.30895/1991-2919-2020-10-2-129-136)
0.00 0
9 Methodological Approaches to Determination of Depressor Subs… (10.30895/1991-2919-2020-10-2-137-141)
0.00 2
10 Current Approaches to the Abnormal Toxicity Test (10.30895/1991-2919-2020-10-2-82-88)
0.00 2
11 Therapeutic Drug Monitoring, CYP2C9 Genotyping and Phenotypi… (10.30895/1991-2919-2020-10-2-89-95)
0.00 0
12 Anti-Tumour Drugs: Planning Preclinical Efficacy and Safety… (10.30895/1991-2919-2020-10-2-96-110)
0.00 6
13 Preclinical Studies in the Pharmaceutical Development Cycle (10.30895/1991-2919-2024-14-3-248-250)
References
0.00 0
14 Non-clinical Studies of Radiopharmaceuticals: Analysis of Na… (10.30895/1991-2919-2024-14-3-251-264)
0.00 2
15 Practical Aspects of Assessing Toxic Lesions of the Peripher… (10.30895/1991-2919-2024-14-3-265-282)
0.00 1
16 Complex Assessment of the Functional State of the Urinary Sy… (10.30895/1991-2919-2024-14-3-283-294)
0.00 1
17 Optimisation of a Cytogenetic Sample Preparation Procedure f… (10.30895/1991-2919-2024-14-3-295-303)
0.00 0
18 Pharmacokinetics Study of a New Isoxazole Derivative in Rats… (10.30895/1991-2919-2024-14-3-304-316)
0.00 1
19 Validation of an Analytical Procedure for Evaluating the Bio… (10.30895/1991-2919-2024-14-3-317-329)
0.00 1
20 Determination of Biological Activity of Gonadotrophins in Ra… (10.30895/1991-2919-2024-14-3-330-337)
0.00 0
21 Basic Principles for Calculating the Required Number of Part… (10.30895/1991-2919-2024-14-3-338-350)
0.00 3
22 Programme for Studying Medicinal Products for Generalised An… (10.30895/1991-2919-2024-14-3-351-361)
0.00 0
23 Improvement of Microbiological Methods for Testing the Quali… (10.30895/1991-2919-2024-14-3-362-369)
0.00 0
24 Recommendations for the Content of a Product Specification F… (10.30895/1991-2919-2024-14-3-370-372)
References
0.00 0
25 Current and Future Pharmacopoeial Requirements for the Quali… (10.30895/1991-2919-2024-14-4-386-399)
0.00 10
26 Drivers of Pharmaceutical Compounding: Regional Experience A… (10.30895/1991-2919-2024-14-4-400-410)
0.00 1
27 Development of Extemporaneous Compounding as an Initiating F… (10.30895/1991-2919-2024-14-4-419-436)
0.00 3
28 Analysis of the Risks Associated with the Functions of a Pha… (10.30895/1991-2919-2024-14-4-437-447)
0.00 1
29 Planning a Clinical Development Programme for Medicinal Prod… (10.30895/1991-2919-2024-14-4-463-473)
0.00 2
30 Metrological Assessment of Analytical Procedures Used for Se… (10.30895/1991-2919-2024-14-4-474-482)
0.00 0
31 Comparison of Incubation Conditions for Microbial Contaminan… (10.30895/1991-2919-2024-14-4-483-492)
0.00 1
32 Role of Intellectual Property in Transferring Pharmaceutical… (10.30895/1991-2919-2024-14-5-500-504)
References ORCID
0.00 0
33 Roles of Individual Institutions in Achieving Pharmaceutical… (10.30895/1991-2919-2024-14-5-505-512)
0.00 1
34 Elements of Strategic Planning of Patent Protection for Phar… (10.30895/1991-2919-2024-14-5-513-520)
0.00 1
35 Application of Public-Private Partnership Mechanisms to Ensu… (10.30895/1991-2919-2024-14-5-521-532)
0.00 2
36 Classification of Cell Therapy Products by Cell Manipulation… (10.30895/1991-2919-2024-14-5-533-546)
0.00 4
37 Kinetic Bacterial Endotoxin Testing Methods: Specifics of An… (10.30895/1991-2919-2024-14-5-547-552)
0.00 0
38 Analysis of Current Approaches to Monitoring the Content of… (10.30895/1991-2919-2024-14-5-553-560)
0.00 1
39 State Pharmacopoeia of the Russian Federation Edition XV: De… (10.30895/1991-2919-2024-14-5-572-579)
0.00 6
40 Development and Validation of an Analytical Procedure for De… (10.30895/1991-2919-2024-14-5-580-589)
0.00 1
41 Experience in the Examination of Bioequivalence Clinical Tri… (10.30895/1991-2919-2024-14-5-590-600)
0.00 0
42 Pharmacopoeias’ and manufacturers’ requirements for the qual… (10.30895/1991-2919-2024-14-6-620-633)
0.00 1
43 Current approaches to the control of process-related impurit… (10.30895/1991-2919-2024-14-6-645-654)
0.00 0
44 Standardisation of the method of residual organic solvent de… (10.30895/1991-2919-2024-14-6-655-662)
0.00 0
45 Quantitative determination of naftifine and its degradation… (10.30895/1991-2919-2024-14-6-673-685)
0.00 0
46 Pharmacy Compounding Regulation in the German Pharmaceutical… (10.30895/1991-2919-2024-590)
0.00 5
47 Chemical Composition and Antioxidant Activity of Ganoderma l… (10.30895/1991-2919-2024-609)
0.00 3
48 Elimination of Exogenous Pollution Influence on the Microele… (10.30895/1991-2919-2024-617)
0.00 4
49 Complex Assessment of the Functional State of the Urinary Sy… (10.30895/1991-2919-2024-631)
0.00 1
50 Calendula Flowers (Calendulae officinalis flos): Methods to… (10.30895/1991-2919-2024-634)
0.00 1